Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yufei Xing

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|November 8, 2021
FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-CancerAnyuan Zhong, Ting Chen, Yufei Xing, et al.
Discover Oncology|April 2, 2026
PHC2 as a novel predictive biomarker and therapeutic target for cisplatin resistance in lung adenocarcinomaXue Pan, Xuejiao Sun, Yufei Xing, et al.
International Medical Case Reports Journal|July 23, 2016
Mirizzi syndrome with an unusual aberrant hepatic duct fistula: a case reportMeng Wang, Yufei Xing, Quangen Gao, et al.
Nursing Reports (Pavia, Italy)|June 25, 2026
Legal Literacy in Clinical Nursing Practice: A Walker and Avant Concept AnalysisYufei Xing, Xiaolong Wang, Enming Zhang, et al.
The Journal of International Medical Research|September 30, 2021
A novel <i>GHR-ALK</i> fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case reportXue Pan, Anyuan Zhong, Yufei Xing, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|September 10, 2014
[Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes]Xue Pan, Yufei Xing, Minhua Shi, et al.
Zhonghua Yi Xue Za Zhi|August 23, 2014
[Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications]Xue Pan, Yufei Xing, Minhua Shi, et al.
Zhonghua Yi Xue Za Zhi|April 29, 2015
[Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism]Jin Zhao, Xue Pan, Yufei Xing, et al.
Molecular Medicine Reports|August 30, 2017
Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathwayYajuan Qian, Ziyan Du, Yufei Xing, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 12, 2026
Recent advances in non-pharmacological interventions for symptom burden management in breast cancer patients treated with ovarian function suppressionYuan Li, Yunyun Chen, Suxing Wang, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|November 8, 2021
FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-CancerAnyuan Zhong, Ting Chen, Yufei Xing, et al.
Discover Oncology|April 2, 2026
PHC2 as a novel predictive biomarker and therapeutic target for cisplatin resistance in lung adenocarcinomaXue Pan, Xuejiao Sun, Yufei Xing, et al.
International Medical Case Reports Journal|July 23, 2016
Mirizzi syndrome with an unusual aberrant hepatic duct fistula: a case reportMeng Wang, Yufei Xing, Quangen Gao, et al.
Nursing Reports (Pavia, Italy)|June 25, 2026
Legal Literacy in Clinical Nursing Practice: A Walker and Avant Concept AnalysisYufei Xing, Xiaolong Wang, Enming Zhang, et al.
The Journal of International Medical Research|September 30, 2021
A novel <i>GHR-ALK</i> fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case reportXue Pan, Anyuan Zhong, Yufei Xing, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|September 10, 2014
[Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes]Xue Pan, Yufei Xing, Minhua Shi, et al.
Zhonghua Yi Xue Za Zhi|August 23, 2014
[Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications]Xue Pan, Yufei Xing, Minhua Shi, et al.
Zhonghua Yi Xue Za Zhi|April 29, 2015
[Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism]Jin Zhao, Xue Pan, Yufei Xing, et al.
Molecular Medicine Reports|August 30, 2017
Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathwayYajuan Qian, Ziyan Du, Yufei Xing, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 12, 2026
Recent advances in non-pharmacological interventions for symptom burden management in breast cancer patients treated with ovarian function suppressionYuan Li, Yunyun Chen, Suxing Wang, et al.
Pageof 4